Companies Dominating the West Syndrome Landscape
- Marinus Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- SK Biopharmaceuticals Co., Ltd.
- Alkem Laboratories Ltd.
- Supernus Pharmaceuticals, Inc.
- Eisai Co., Ltd.
- Abbott Laboratories
- Upsher-Smith Laboratories, LLC.
- Pfizer Inc.
- H. Lundbeck A/S
- UCB S.A.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
West Syndrome Market in 2025 is assessed at USD 1.16 billion.
The global market size was valued at around USD 1.11 billion in 2024 and is projected to grow at a CAGR of more than 5.5%, reaching USD 2.23 billion revenue by 2037.
North America is forecast to yield largest share by 2037, fueled by escalation in the number of people living with traumatic brain injuries.
The major players in the market include Marinus Pharmaceuticals, Inc., SK Biopharmaceuticals Co., Ltd., Alkem Laboratories Ltd., Supernus Pharmaceuticals, Inc., Eisai Co., Ltd., Abbott Laboratories, Upsher-Smith Laboratories, LLC., Pfizer Inc., H. Lundbeck A/S, UCB S.A.